Genetics and Parkinson's Disease (2019)

During this talk during Parkinson Society BC's 2018 Annual General Meeting, Dr. Matt Farrer, a University of British Columbia professor of medical genetics, shares insights into his journey of Parkinson's research, focusing on the significance of genetic understanding in the disease's development. He discusses the role of the alpha-synuclein gene and its potential as a target for treatment, leading to new possibilities for drug therapies and clinical trials. The talk highlights his research on the translational cycle of discovering genes associated with Parkinson's disease and their functional implications, particularly in families with inherited forms of the condition.

Dr. Farrer's discussion also delves into the study of LRRK2 variability in Parkinson's disease, addressing the challenges faced by drug companies in conducting clinical trials and the potential biological benefits associated with LRRK2 mutations. The prevalence of LRRK2 variants in various populations, including North Africa and Asia, is explored, emphasizing the potential for targeted drug development. Additionally, he emphasizes the importance of genetic research in understanding Parkinson's disease and its potential implications for other diseases, with a patient sharing their experience participating in genetic research and addressing concerns about privacy and predispositions to other conditions.

**Disclaimer: These sessions are designed to provide general education and are not intended for individual advice and/or clinical care. The information conveyed in this recording was accurate at the time of presentation.**